A Phase I/II open-label, multi-center study of BGB-A317 evaluating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of BGB-A317 in Chinese patients with advanced solid tumors.

Trial Profile

A Phase I/II open-label, multi-center study of BGB-A317 evaluating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of BGB-A317 in Chinese patients with advanced solid tumors.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs BGB A317 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Sep 2017 Results of Phase 1(n=20) presented in a BeiGene media release.
    • 28 Sep 2017 According to a BeiGene media release, company has presented preliminary Phase 1 data(n=20) from this trial at the 20th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO), Sep 2017.
    • 21 Sep 2017 According to a BeiGene media release, company will present preliminary data from this trial at the 20th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO), Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top